Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study

References

• European Medicines Agency [Internet]. Omnitrope® summary of product characteristics, updated 2023; 2008. Available from: https://www.ema.europa.eu/en/documents/product-information/omnitrope-epar-product-information_en.pdf. Accessed June 30, 2023.
   Google Scholar
• Tidblad A. The history, physiology and treatment safety of growth hormone. Acta Paediatr. 2022;111(2):215–224. doi:10.1111/apa.15948
   PubMed Web of Science ®Google Scholar
• Ranke MB, Wit JM. Growth hormone – past, present and future. Nat Rev Endocrinol. 2018;14(5):285–300. doi:10.1038/nrendo.2018.22
   PubMed Web of Science ®Google Scholar
• Dahlgren J, Noordam C. Growth, endocrine features, and growth hormone treatment in Noonan syndrome. J Clin Med. 2022;11(7):2034. doi:10.3390/jcm11072034
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [Internet]. Omnitrope® European public assessment report (EPAR), updated 2018; 2008. Available from: https://www.ema.europa.eu/en/documents/overview/omnitrope-epar-summary-public_en.pdf. Accessed June 30, 2023.
   Google Scholar
• López-Siguero J, Borrás Pérez MV, Balser S, Khan-Boluki J. Long-term safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of Spanish growth hormone deficient children: results of a phase III study. Adv Ther. 2011;28(10):879–893. doi:10.1007/s12325-011-0063-8
   PubMed Web of Science ®Google Scholar
• Romer T, Saenger P, Peter F, et al. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study. Horm Res. 2009;72(6):359–369. doi:10.1159/000249164
   PubMed Web of Science ®Google Scholar
• Pfäffle R, Schwab KO, Marginean O, et al. Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® in children requiring growth hormone treatment. Ther Adv Endocrinol Metab. 2013;4(1):3–11. doi:10.1177/2042018813479644
   PubMedGoogle Scholar
• Iughetti L, Tornese G, Street ME, et al. Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study. Ital J Pediatr. 2016;42(1):93. doi:10.1186/s13052-016-0302-3
   PubMedGoogle Scholar
• Pfäffle R, Bidlingmaier M, Kreitschmann-Andermahr I, et al. Safety and effectiveness of Omnitrope®, a biosimilar recombinant human growth hormone: more than 10 years’ experience from the PATRO Children study. Horm Res Paediatr. 2020;93(3):154–163. doi:10.1159/000508190
   PubMed Web of Science ®Google Scholar
• Hermanussen M, Assmann C, Wöhling H, Zabransky M. Harmonizing national growth references for multi-centre surveys, drug monitoring and international postmarketing surveillance. Acta Paediatr. 2012;101(1):78–84. doi:10.1111/j.1651-2227.2011.02415.x
   PubMed Web of Science ®Google Scholar
• Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95(1):167–177. doi:10.1210/jc.2009-0178
   PubMed Web of Science ®Google Scholar
• Child CJ, Zimmermann AG, Chrousos GP, et al. Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program. J Clin Endocrinol Metab. 2019;104(2):379–389. doi:10.1210/jc.2018-01189
   PubMed Web of Science ®Google Scholar
• Cutfield WS, Lindberg A, Rapaport R, Wajnrajch MP, Saenger P. Safety of growth hormone treatment in children born small for gestational age: the US trial and KIGS analysis. Horm Res. 2006;65(Suppl 3):153–159. doi:10.1159/000091719
   PubMedGoogle Scholar
• Sävendahl L, Pournara E, Pedersen BT, Blankenstein O. Is safety of childhood growth hormone therapy related to dose? Data from a large observational study. Eur J Endocrinol. 2016;174(5):681–691. doi:10.1530/eje-15-1017
   PubMed Web of Science ®Google Scholar
• Sävendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012;97(2):E213–E217. doi:10.1210/jc.2011-2882
   PubMed Web of Science ®Google Scholar
• Wilton P, Mattsson AF, Darendeliler F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J Pediatr. 2010;157(2):265–270. doi:10.1016/j.jpeds.2010.02.028
   PubMed Web of Science ®Google Scholar
• Poidvin A, Weill A, Ecosse E, Coste J, Carel JC. Risk of diabetes treated in early adulthood after growth hormone treatment of short stature in childhood. J Clin Endocrinol Metab. 2017;102(4):1291–1298. doi:10.1210/jc.2016-3145
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Cooke R, Beckers D, et al. Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study. J Clin Endocrinol Metab. 2017;102(5):1661–1672. doi:10.1210/jc.2016-2046
   PubMed Web of Science ®Google Scholar
• Maghnie M, Ranke MB, Geffner ME, et al. Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort. J Clin Endocrinol Metab. 2022;107(12):3287–3301. doi:10.1210/clinem/dgac517
   PubMed Web of Science ®Google Scholar
• Coutant R, Bosch Muñoz J, Dumitrescu CP, et al. Effectiveness and overall safety of NutropinAq® for growth hormone deficiency and other paediatric growth hormone disorders: completion of the International Cooperative Growth Study, NutropinAq® European Registry (iNCGS). Front Endocrinol. 2021;12:676083. doi:10.3389/fendo.2021.676083
   PubMed Web of Science ®Google Scholar
• Sävendahl L, Polak M, Backeljauw P, et al. Long-term safety of growth hormone treatment in childhood: two large observational studies: NordiNet IOS and ANSWER. J Clin Endocrinol Metab. 2021;106(6):1728–1741. doi:10.1210/clinem/dgab080
   PubMed Web of Science ®Google Scholar
• Poidvin A, Touzé E, Ecosse E, et al. Growth hormone treatment for childhood short stature and risk of stroke in early adulthood. Neurology. 2014;83(9):780–786. doi:10.1212/wnl.0000000000000737
   PubMed Web of Science ®Google Scholar
• Ogle GD, James S, Dabelea D, et al. Global estimates of incidence of type 1 diabetes in children and adolescents: results from the International Diabetes Federation Atlas, 10th edition. Diabetes Res Clin Pract. 2022;183:109083. doi:10.1016/j.diabres.2021.109083
   PubMed Web of Science ®Google Scholar
• Wu H, Patterson CC, Zhang X, et al. Worldwide estimates of incidence of type 2 diabetes in children and adolescents in 2021. Diabetes Res Clin Pract. 2022;185:109785. doi:10.1016/j.diabres.2022.109785
   PubMed Web of Science ®Google Scholar
• Craig ME, Cowell CT, Larsson P, et al. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol. 2006;65(2):178–185. doi:10.1111/j.1365-2265.2006.02570.x
   PubMed Web of Science ®Google Scholar
• Damen L, Donze SH, Kuppens RJ, et al. Three years of growth hormone treatment in young adults with Prader-Willi syndrome: sustained positive effects on body composition. Orphanet J Rare Dis. 2020;15(1):163. doi:10.1186/s13023-020-01440-6
   PubMed Web of Science ®Google Scholar
• Lindgren AC, Lindberg A. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database). Horm Res. 2008;70(3):182–187. doi:10.1159/000145019
   PubMedGoogle Scholar
• Bonfig W, Lindberg A, Carlsson M, et al. Efficacy of growth hormone treatment in children with type 1 diabetes mellitus and growth hormone deficiency—an analysis of KIGS data. J Pediatr. 2018;198:260–264. doi:10.1016/j.jpeds.2018.02.035
   PubMed Web of Science ®Google Scholar
• Polak M, Blair J, Kotnik P, Pournara E, Pedersen BT, Rohrer TR. Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet® International Outcome Study. Eur J Endocrinol. 2017;177(5):421–429. doi:10.1530/eje-16-1024
   PubMed Web of Science ®Google Scholar
• Reiter EO, Price DA, Wilton P, Albertsson-Wikland K, Ranke MB. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab. 2006;91(6):2047–2054. doi:10.1210/jc.2005-2284
   PubMed Web of Science ®Google Scholar
• Sandoz. Data on file: Omnitrope periodic safety update report (PSUR); 2022.
   Google Scholar